February 06, 2025
2 min watch
Save
VIDEO: ‘Excellent efficacy-to-tolerability ratio’ seen with aceclidine presbyopic drop
KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2025, Jason Bacharach, MD, of North Bay Eye Associates, shares data on an aceclidine-based presbyopia-correcting eye drop from Lenz Therapeutics.
“This product has been around for many years as a glaucoma agent in Europe,” he said. “But it’s actually a very ineffective glaucoma agent, and that is what makes it amazing for presbyopia. This product works specific to the iris to create miosis. It has no effect on the ciliary body.”
According to Bacharach, patients who use the drop have “excellent efficacy-to-tolerability ratio,” and it met all prespecified endpoints in the phase 3 CLARITY study.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Bacharach reports receiving grant/research support from Lenz Therapeutics.
Read more about